↑Baldwin CT, Hoth CF, Macina RA, Milunsky A(August 1995).“Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature”.American Journal of Medical Genetics58(2): 115–22.doi:10.1002/ajmg.1320580205.PMID8533800.
↑Jun S, Desplan C(September 1996).“Cooperative interactions between paired domain and homeodomain”.Development122(9): 2639–50.doi:10.1242/dev.122.9.2639.PMID8787739.
↑Wilson D, Sheng G, Lecuit T, Dostatni N, Desplan C(November 1993).“Cooperative dimerization of paired class homeo domains on DNA”.Genes & Development7(11): 2120–34.doi:10.1101/gad.7.11.2120.PMID7901121.
↑Phelan SA, Loeken MR(July 1998).“Identification of a new binding motif for the paired domain of Pax-3 and unusual characteristics of spacing of bipartite recognition elements on binding and transcription activation”.The Journal of Biological Chemistry273(30): 19153–9.doi:10.1074/jbc.273.30.19153.PMID9668101.
↑Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ, Barr FG(July 1995).“Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains”.Oncogene11(1): 119–30.PMID7624119.
↑Lang D, Epstein JA(April 2003).“Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer”.Human Molecular Genetics12(8): 937–45.doi:10.1093/hmg/ddg107.PMID12668617.
↑Diao Y, Guo X, Li Y, Sun K, Lu L, Jiang L, Fu X, Zhu H, Sun H, Wang H, Wu Z(August 2012).“Pax3/7BP is a Pax7- and Pax3-binding protein that regulates the proliferation of muscle precursor cells by an epigenetic mechanism”.Cell Stem Cell11(2): 231–41.doi:10.1016/j.stem.2012.05.022.PMID22862948.
↑Hollenbach AD, McPherson CJ, Lagutina I, Grosveld G(April 2002).“The EF-hand calcium-binding protein calmyrin inhibits the transcriptional and DNA-binding activity of Pax3”.Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression1574(3): 321–8.doi:10.1016/s0167-4781(02)00230-0.PMID11997098.
↑Boutet SC, Disatnik MH, Chan LS, Iori K, Rando TA(July 2007).“Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors”.Cell130(2): 349–62.doi:10.1016/j.cell.2007.05.044.PMID17662948.
↑Buckingham M, Relaix F(2007).“The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions”.Annual Review of Cell and Developmental Biology23: 645–73.doi:10.1146/annurev.cellbio.23.090506.123438.PMID17506689.
↑Epstein DJ, Vekemans M, Gros P(November 1991).“Splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3”.Cell67(4): 767–74.doi:10.1016/0092-8674(91)90071-6.PMID1682057.
↑Barr FG(September 2001).“Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma”.Oncogene20(40): 5736–46.doi:10.1038/sj.onc.1204599.PMID11607823.
↑Arndt CA, Crist WM(July 1999).“Common musculoskeletal tumors of childhood and adolescence”.The New England Journal of Medicine341(5): 342–352.doi:10.1056/NEJM199907293410507.PMID10423470.
↑Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, Emanuel BS, Rovera G, Barr FG(November 1993).“Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma”.Nature Genetics5(3): 230–5.doi:10.1038/ng1193-230.PMID8275086.
↑Barr FG, Chatten J, D'Cruz CM, Wilson AE, Nauta LE, Nycum LM, Biegel JA, Womer RB(February 1995).“Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas”.JAMA273(7): 553–557.doi:10.1001/jama.1995.03520310051029.PMID7530783.
↑Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ(July 2006).“Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas”.Cancer Research66(14): 6936–46.doi:10.1158/0008-5472.CAN-05-4578.PMID16849537.
↑Fritchie KJ, Jin L, Wang X, Graham RP, Torbenson MS, Lewis JE, Rivera M, Garcia JJ, Schembri-Wismayer DJ, Westendorf JJ, Chou MM, Dong J, Oliveira AM(December 2016).“Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases”.Histopathology69(6): 930–936.doi:10.1111/his.13045.PMID27454570.
12Xia L, Huang Q, Nie D, Shi J, Gong M, Wu B, Gong P, Zhao L, Zuo H, Ju S, Chen J, Shi W(July 2013).“PAX3 is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells”.Brain Research1521: 68–78.doi:10.1016/j.brainres.2013.05.021.PMID23701726.
12Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, Schäfer BW(February 2001).“PAX3 is expressed in human melanomas and contributes to tumor cell survival”.Cancer Research61(3): 823–6.PMID11221862.
↑Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ, Bennicelli JL(November 1999).“Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines”.Cancer Research59(21): 5443–8.PMID10554014.
↑Jones AM, Mitter R, Poulsom R, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ(December 2008).“mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours”.The Journal of Pathology216(4): 408–17.doi:10.1002/path.2439.PMID18937276.
↑Liu Q, Yang G, Qian Y(April 2017).“Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway”.Molecular Carcinogenesis56(4): 1312–1321.doi:10.1002/mc.22593.PMID27859625.
Kubo T, Shimose S, Fujimori J, Furuta T, Ochi M(2015).“Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis”.Critical Reviews in Oncology/Hematology96(1): 46–53.doi:10.1016/j.critrevonc.2015.04.012.PMID26008753.
Buckingham M, Relaix F(2015).“PAX3 and PAX7 as upstream regulators of myogenesis”.Seminars in Cell & Developmental Biology44: 115–25.doi:10.1016/j.semcdb.2015.09.017.PMID26424495.
Medic S, Ziman M(2009).“PAX3 across the spectrum: from melanoblast to melanoma”.Critical Reviews in Biochemistry and Molecular Biology44(2–3): 85–97.doi:10.1080/10409230902755056.PMID19401874.